InhaTarget Therapeutics is a project that benefits from the support of many partners, closely collaborating for the success of this venture.
The Technology Transfer Office (TTO) of the ULB is in charge of the technology transfer from the ULB to the InhaTarget Therapeutics spin-off.
The role of the TTO is to promote collaborative research and business development between the ULB and its external partners (businesses, public bodies, competition clusters, professional associations, etc.), as well as participating in local and regional development.
The CMMI is the privileged partner of InhaTarget Therapeutics for microscopy and in vivo imaging activities.
The CMMI proposes all kinds of analysis, from molecules to small animals. It provides industrial and academic labs with an extremely broad range of cutting edge imaging instruments and techniques.
The i-Tech Incubator is the partner of the InhaTarget project for all business planning and business model matters.
As a start-up accelerator, the i-Tech Incubator follows a four-ingredient recipe: a team of programme managers eager to make things happen, an international network of seasoned industry professionals ready to put their expertise to work in start-ups, an international network of seed venture capitals with field focus and a dedicated hosting infrastructure where start-ups can work and come together.
The Walloon Region is at the basis of the whole venture as it financially supports the InhaTarget project in its scientific validation and business planning matters.
Activities by the Walloon Region support entrepreneurship training for researchers and the creation of spin-off companies through to the development and validation of new products, processes or services intended to be valorised industrially in the short term.
The Analytical Platform of the Faculty of Pharmacy is the privileged partner of InhaTarget Therapeutics for analytical analyses and method development.
Services offered by the platform include analysis and formulation possibilities in the pharmaceutical, clinical and agricultural domains through direct access to several apparatuses and the expertise of the different laboratories of the Faculty.
The Jules Bordet Institute is one of the clinical partners of InhaTarget Therapeutics, through the grandfathering of the start-up project by Pr. Thierry Berghmans, Head of the Thoracic Oncology Clinic.
As an integrated multidisciplinary center, unique in Belgium and internationally renowned, the Jules Bordet Institute is a hospital entirely devoted to patients suffering from cancerous diseases. The Institute also conducts important clinical research activities in oncology.
The Erasmus Hospital is one of the clinical partners of InhaTarget Therapeutics, through the grandfathering of the start-up project by Pr. Paul De Vuyst, Pulmonologist.
The Erasmus Hospital is the academic hospital of the ULB. An academic, private and secular institution, it jointly fulfills three missions: patient care, teaching and research.
BePharBel is a pharma partner of InhaTarget Therapeutics through the strategic grandfathering of the start-up project by Mr. Vincent Stephenne, CEO of BePharBel.
BePharBel Manufacturing’s mission is to develop and manufacture innovative pharmaceutical and parapharmaceutical products.
SMB Lab is a pharma partner of InhaTarget Therapeutics through the strategic grandfathering of the start-up project by Dr. Thami Sebti, Head of Inhalation Products.
SMB Lab uses its experience, its know-how and the best existing technologies to identify and develop its own pharmaceutical forms that are designed to improve patients outcomes.